Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence

Closing remarks

Date

20 Oct 2023

Session

Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence

Topics

Tumour Site

Urothelial Cancer;  Prostate Cancer

Presenters

All Speakers

Authors

A.G. Omlin1, A.J. Birtle2, A. Speakers3

Author affiliations

  • 1 Medical Onocolgy And Haematology Department, OnkoZentrum Zürich, 8038 - Zurich/CH
  • 2 Rosemere Cancer Centre, Royal Preston Hospital, PR2 9HT - Preston/GB
  • 3 ESMO - European Society for Medical Oncology, GX11 1AA - Lugano/CH

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Opening remarks & introduction

Presenter: All Speakers

Session: Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence

Resources:

Webcast

Interactive Q&A session

Presenter: All Speakers

Session: Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.